로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > IL-6

IL-6

요약

Name:Interleukin-6
Target Synonym:CTL Differentiation Factor,Interleukin 6 (Interferon, Beta 2),HSF,B-cell stimulatory factor 2,Interferon beta-2,IL6,IFNB2,IL-6,Interleukin-6,Interleukin 6,Hybridoma Growth Factor,IFN-Beta-2,BSF-2,CDF,B-Cell Differentiation Factor,Interferon, Beta 2,Interleukin BSF-2,BSF2,HGF
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

라이센싱

항목 적응증 연구 단계 합작 수요
NSS-21001 Cancer cachexia Preclinical candidate compound identified License-out or co-development.

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

IL6-H8218-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).

IL6-H4218-Cell-based assay
 IL-6 CELL

Human IL-6, premium grade (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2856-0.3636 ng/mL (Routinely tested).

IL6-H8218-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

IL6-H4218-BLI
 IL-6 BLI

Loaded Human IL-6 R alpha, Fc Tag (Cat. No. ILR-H5259) on Protein A Biosensor, can bind Human IL-6, premium grade(Cat. No. IL6-H4218) with an affinity constant of 35.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

IL6,Interleukin-6,BSF2,HSF,IFNB2

Background

Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and  IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor  and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Luminol sodium MP-1032 Approved Selvim, Metrio Psoriasis; Immune System Diseases null 1997-01-01 Immune System Diseases; Psoriasis Details
Siltuximab cCLB-8; CNTO-328 Approved Johnson & Johnson Sylvant Mainland China Multicentric Castleman's Disease (MCD) Beigene (Beijing) Biotechnology Co Ltd 2014-04-23 Monoclonal Gammopathy of Undetermined Significance; Leukemia, Large Granular Lymphocytic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Lung Neoplasms; Primary Myelofibrosis; Colorectal Neoplasms; Castleman Disease; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Ovarian Neoplasms; Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Polycythemia Vera; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Cytokine Release Syndrome; Head and Neck Neoplasms Details
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Japan Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 Waldenstrom Macroglobulinemia; Sarcoma; Prostatic Neoplasms; Arachnoiditis; Cholangitis, Sclerosing; Gastrointestinal Hemorrhage; Osteosarcoma; Pancreatitis, Chronic; Retinoblastoma; Sarcoma, Ewing; Lymphoma, Mantle-Cell; Prostatitis; Colitis, Ulcerative; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Erythema Nodosum; Leprosy, Lepromatous; Endometrial Neoplasms; Appendiceal Neoplasms; Pelvic Pain; Angiodysplasia; Glioma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular; Amyotrophic Lateral Sclerosis; Vascular Malformations; Crohn Disease; Precancerous Conditions; Mycobacterium avium-intracellulare Infection; Idiopathic Pulmonary Fibrosis; Leukemia; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Liver Neoplasms; Cough; Telangiectasia, Hereditary Hemorrhagic; Mycobacterium Infections; Rhabdomyosarcoma; Arteriovenous Malformations; Inflammatory Bowel Diseases; Stomatitis, Aphthous; Gastric Antral Vascular Ectasia; Spondylitis, Ankylosing; Myelodysplastic Syndromes; HIV Infections; Coronavirus Dise Details
Pomalidomide IMID-4047; CDC-394; CC-4047; IMiD-1 Approved Celgene Corp Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 Mainland China Multiple Myeloma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2013-02-08 Lung Diseases, Interstitial; Neoplasm Metastasis; Anemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Sarcoma, Kaposi; Lymphoma, Non-Hodgkin; Primary Myelofibrosis; Amyloidosis; Sarcoma; Prostatic Neoplasms; Lymphoma, Follicular; Central Nervous System Neoplasms; Bone Marrow Neoplasms; Pulmonary Fibrosis; Multiple Myeloma; Graft vs Host Disease; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Neoplasms; Lymphoma, B-Cell; Medulloblastoma; Solid tumours Details
Lenalidomide CC-5013; IMiD-3; ENMD-0997; STAR-LLD; CDC-501; IMID-5013; CDC-5013 Approved Celgene Corp Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo EU Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular Celgene Europe Bv 2005-12-27 Lymphoma, T-Cell, Cutaneous; Lymphoma, Follicular; Reflex Sympathetic Dystrophy; Radiculopathy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Histiocytosis, Langerhans-Cell; Prostatic Neoplasms; Demyelinating Diseases; Gliosarcoma; Primary Myelofibrosis; Histiocytic Sarcoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Thrombocytopenia; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Thyroid Neoplasms; Glioma; Leukemia, Monocytic, Acute; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Squamous Cell; Epstein-Barr Virus Infections; Cachexia; Leukemia, Lymphocytic, Chronic, B-Cell; Crohn Disease; Melanoma; Complex Regional Pain Syndromes; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Mental Disorders; Neoplasms; Lymphoma, B-Cell, Marginal Zone; HIV Infections; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Liver Neoplasms; Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia, Erythroblastic, Acute; Hematologic Diseases; Anemia; Paraproteinemias; Pain; Myelodys Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Tocilizumab biosimilar (Mycenax Biotech) Phase 1 Clinical Mycenax Biotech Inc Arthritis, Rheumatoid Details
Anti-interleukin-6 receptor monoclonal antibody (Biocad) Phase 2 Clinical Biocad Autoimmune Diseases Details
Wogonin Phase 1 Clinical Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University Respiratory Tract Infections; Neoplasms Details
DMT-210 DMT-200; DMT-210; DMT-220; SIG-990 Signum Dermalogix Details
FB-704A FB-704; FB-704A Fountain Biopharma Details
AMG-220 C-326; AMG-220 Amgen Inc Details
Monoclonal Antibody (Mab) sB24M Phase 1 Clinical Pyoderma Gangrenosum Details
Isomyosamine MYMD-1 Phase 2 Clinical Mymd Pharmaceuticals Inc Healthy Aging Details
Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences) EN-3348 Prometic Life Sciences Details
MEDI-5117 WBP-216; MEDI-5117 Phase 1 Clinical Wuxi Apptec Co Ltd, Medimmune Arthritis, Rheumatoid Details
PF-04236921 PF-4236921; PF-04236921 Pfizer Pharmaceuticals Ltd (China) Details
Ziltivekimab COR-001 Phase 3 Clinical Astrazeneca Pharmaceutical Co Ltd Cardiovascular Diseases; Renal Insufficiency, Chronic Details
Efprezimod alfa CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 Phase 1 Clinical Oncoimmune Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19) Details
Gerilimzumab GB-224; RYI-008; ARGX-109 Phase 1 Clinical Argenx Se Arthritis, Rheumatoid Details
Olokizumab CDP-6038; Anti-IL6-UCB Ucb Details
Ensereptide PXL-01 Phase 3 Clinical Promore Pharma Post-surgical adhesions; Cicatrix Details
Sirukumab BA-003; CNTO-136 Phase 2 Clinical Glaxosmithkline Plc, Janssen Global Services Llc Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lupus Erythematosus, Cutaneous; Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma Details
RO-7200220 RO-7200220 Phase 2 Clinical F. Hoffmann-La Roche Ltd Diabetic macular oedema Details
Clazakizumab ALD-518; ALD518-003; BMS-645429; BMS-945429 Phase 3 Clinical Alder Biopharmaceuticals Plaque, Atherosclerotic; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Fatigue; Graft vs Host Disease; Rejection of organ transplantation; Arthritis, Psoriatic; Asthma; Cachexia; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Stomatitis; Kidney Failure, Chronic Details

This web search service is supported by Google Inc.

totop